NAT2 gene polymorphism and sporadic colorectal cancer. Prevalence, tumor stage and prognosis. A preliminary study in 70 patients

Journal of Gastrointestinal and Liver Diseases

Volumn 15, Issue 4, 2006, Pages 347-353

  Osian, Gelu ^a   Procopciuc, Lucia ^a   Vlad, Liviu ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Colorectal cancer; NAT2 gene; Polymorphism; Prevalence; Prognosis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ACETYLATOR PHENOTYPE; ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CARCINOGENESIS; COLON CARCINOGENESIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAT2 GENE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT;

ACETYLATION; AGED; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; ROMANIA;

EID: 33846271771     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Freedman A. Somatic alterations and metabolic polymorphisms. IARC Sci Pub1999; 37-50.
2. Windmill KF, Gaedigk A, de al Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 2000;54: 19-29.
3. Ilett KF, Ingram DM, Carpenter DS, et al. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 1994;47:914-917.
4. Turesky RJ, Lang NP, Butler MA, Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 1991; 12:1839-1845
5. Pande JN, Pande A, Singh SP. Acetylator status, drug metabolism and disease. Natl Med J India 2003;16:24-26.
6. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 1995;16: 39-52.
7. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001;10:725-731.
8. Barrett JH, Smith G, Waxman R, et al. Colorectal Cancer Study Group. Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis 2003;24:275-282.
9. Patrianakos C, Hoffmann D. Chemical studies on tobacco smoke. LXIV. On the analysis of aromatic amines in cigarette smoke. J Anal Toxicol 1979;3:150-154.
10. Manabe S, Tohyama K, Wada O, Aramaki T. Detection of a carcinogen, 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) in cigarette smoke condensate. Carcinogenesis 1991;12: 1945-1947.
11. Hughes HB, Biehl JP, Jones AP, Schmidt L H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954;70:266-273.
12. Jenne JW. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. J Clin Investig 1965;44:1992-2002.
13. Evans DA, White TA. Human acetylation polymorphism. J Lab Clin Med 1964;63:394-403.
14. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-422.
15. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-127.
16. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17:459-464.
17. Grant DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res 1997;376:61-70.
18. Cascorbi I, Roots I. Pitfalls in N-Acetyltransferase 2 genotyping. Pharmacogenetics 1999;9:123-127.
19. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
20. Vesell ES, Gaylor DW. Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods. Pharmacogenetics 1995;5:18-23.
21. Evans DA. N-acetyltransferase. Pharmacol Ther 1989;42:157-234
22. Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA, Pavlova MV. Acetylator phenotype in patients with breast cancer. Oncology 1978;35:185-188.
23. Welfare MR, Bassendine MF, Welfare MR, Daly A.K. Caffeine phenotyping in patients with familial adenomatous polyposis may shed light on sporadic colon cancer and acetylator status. Gut 1996;38:153.
24. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
25. Hickman D, Risch A, Buckle V, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994;297:441-445.
26. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-1692
27. Hirvonen A. Polymorphic NATs and cancer predisposition. IARC Sci Pub 1999;251-270.
28. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-592.
29. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992; 267:18140-18147.
30. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-5241.
31. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992; 2: 217-226.
32. Lin JJ, Han CY, Link B K, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993;52:827-834.
33. Ferguson RJ, Doll MA, Rustan TD, Gray K, Hein DW. Cloning, expression, and functional characterization of two mutant (NAT2 191 and NAT2 341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metab Dispos 1994;22:371-376.
34. Hardingham JE, Butler WJ, Roder D et al. Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 1998;42:669-672.
35. Hubbard AL, Harrison DJ, Moyes C, Wyllie AH, Cunningham C, Mannion E, Smith CA. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut 1997;41:229-234.
36. Lee EJ, Zhao B, Seow-Choen F. Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population. Pharmacogenetics 1998;8:513-517.
37. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N- acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998;19:37-41.
38. Frazier ML, O'Donnell FT, Kong S, et al. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 2001;61:1269-1271.
39. Tamer L, Ercan B, Ates NA, et al. N-acetyltransferase 2 gene polymorphism in patients with colorectal carcinoma. Cell Biochem Funct 2004 (Published Online: 22 Dec 2004).
40. Kiss I, Nemeth A, Bogner B, et al. Polymorphisms of glutathione-S- transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer. Anticancer Res 2004;24:3965-3970.
41. Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B, Leppert M. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1998;7:1079-1084.
42. Katoh T, Boissy R, Nagata N, et al. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer 2000:1;85:46-49.
43. Butler WJ, Ryan P, Roberts-Thomson IC. Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol 2001; 16:631-635.
44. Tiemersma EW, Kampman E, Bueno de Mesquita HB, et al. Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: results from a Dutch prospective study. Cancer Causes Control 2002;13:383-393.
45. de Jong MM, Nolte IM, te Meerman GJ, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2002;11:1332-1352.
46. Wu AH, Paganini-Hill A, Ross RK, Henderson BE. Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer 1987;55:687-94.
47. Chen J, Stampfer MJ, Hough HL et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998;58:3307-3311.
48. de Kok TM, van Maanen JM. Evaluation of fecal mutagenicity and colorectal cancer risk. Mutat Res 2000;463:53-101.
49. Houlston R, Crabtree M, Phillips R, Crabtree M, Tomlinson I. Explaining differences in the severity of familial adenomatous polyposis and the search for modifier genes. Gut 2001;48:1-485.
50. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995;25:27-65.
51. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991;1:4-19.
52. Loktionov A, Watson MA, Stebbings WS, Speakman CT, Bingham SA. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett 2003;189:189-196.
53. Ferraz JM, Zinzindohoue F, Lecomte T, et al. Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer. Int J Cancer 2004;110:183-187.
54. Chen K, Jiang QT, He HQ. Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol 2005;11:331-335.
55. He LJ, Yu YM, Qiao F, Liu JS, Sun XF, Jiang LL. Genetic polymorphisms of N-acetyltransferase 2 and colorectal cancer risk. World J Gastroenterol 2005;11:4268-4271.